Daiichi posts another Ranbaxy-related loss; Lilly wins FDA nod for combo diabetes pill;

@FiercePharma: Two chairmen replaced as J&J takes another crack at overhauling McNeil, WSJ reports. Article | Follow @FiercePharma

> Japan's Daiichi Sankyo saw its latest earnings weighed down once again by majority-owned subsidiary Ranbaxy Laboratories, the Indian drugmaker that recently signed a consent decree with FDA. More

> Eli Lilly ($LLY) won the FDA nod for its diabetes treatment Jentadueto, which combines the commonly used treatment metformin with its newer drug Tradjenta, sold in partnership with Germany's Boehringer Ingelheim. News

> Biogen Idec ($BIIB) said spending on drug trials and launches will cause lower-than-expected earnings for 2012, as its multiple sclerosis drug Tysabri posted sales growth of 14%, lower than Wall Street estimates. Report

> The standard diabetes therapy metformin was associated with fewer cases of pancreatic cancer, a study showed, while other diabetes drugs were found to be associated with a higher risk of the disease. Article

> Generics maker Lannett won FDA approval for its version of the Watson Pharmaceuticals ($WPI) blood-pressure drug Microzide. Story

> The drug distributor McKesson agreed to pay $918 million for marketing and franchising businesses associated with 1,000 independent Canadian pharmacies. Report

> Regulators in Saudi Arabia have proposed a code of ethics for companies manufacturing and marketing pharmaceutical products. More

Biotech News

@FierceBiotech: Lilly's losses put pressure on key Alzheimer's program. How will Lechleiter's R&D strategy fare? Article | Follow @FierceBiotech

@JohnCFierce: Ketamine ("Special K") for depression? Being studied in IV form, also new pill. Story | Follow @JohnCFierce

@RyanMFierce: Lilly ($LLY) gained an FDA nod for a linagliptin-metformin combo pill for diabetes partnered with Boehringer. News | Follow @RyanMFierce

@MarkHFierce: A 2,200 year old mummy had prostate cancer. Researchers say the finding proves cancer is caused by genetics. More | Follow @MarkHFierce

> BREAKING: Vertex nabs expedited FDA OK on breakthrough CF drug. News

> Researchers study 'Special K' drug as potential tonic for depression. Story

> Biogen boosts R&D budget after research cutbacks. More

> Pfizer targets approval for new menopause drug. Article

> Analysts give Actelion's key lung drug 63% odds of success. Story

> BioSante axes 25% of workforce after big miss in female libido gel trials. News

Research News

> New target could be key to beating back methamphetamine addiction. More

> Meet cancer's latest enemy: grape seed extract. Article

> Team finds 2 mutations that cause pediatric brain cancer. More

> Mutated melanoma receptor heightens diabetes risk. Story

> Nearly $11M to fund new Joslin Diabetes Center research facility. Item

Pharma Manufacturing News

> Teva's Cephalon recalls leukemia drug over fragments in vial. News

> Pfizer workers at manufacturing hub sue over whiplashed retirement plans. Article

> Company whistleblower program part of Ranbaxy consent decree. News

> Gutted J&J consumer healthcare plant another year from reopening. Story

> Medicines Company, APP settlement includes manufacturing agreement. Item

And Finally... Skin patches may be a better delivery method for allergy-fighting immunotherapy, a study found. Report

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.